Clinical and metabolic risk factor evaluation in young adults with kidney stones

Francisco R. Spivacow(Universidad del Salvador), José Zanchetta(Universidad del Salvador), Elisa Elena del Valle(Universidad del Salvador), Irene Calviño(Hospital Fernández), Armando Negri(Universidad del Salvador)

International Urology and Nephrology

August 3, 2009

10.1007/s11255-009-9623-0

Cited by 56

Related Papers

Effect of Parathyroid Hormone (1-34) on Fractures and Bone Mineral Density in Postmenopausal Women with Osteoporosis

|New England Journal of Medicine|2001|4.6k

Denosumab for Prevention of Fractures in Postmenopausal Women with Osteoporosis

|New England Journal of Medicine|2009|3.5k

Romosozumab in Postmenopausal Women with Low Bone Mineral Density

|New England Journal of Medicine|2014|1.2k

Efficacy of Bazedoxifene in Reducing New Vertebral Fracture Risk in Postmenopausal Women With Osteoporosis: Results From a 3-Year, Randomized, Placebo-, and Active-Controlled Clinical Trial

|Journal of Bone and Mineral Research|2008|508

Effects of teriparatide versus alendronate for treating glucocorticoid‐induced osteoporosis: Thirty‐six–month results of a randomized, double‐blind, controlled trial

|Arthritis & Rheumatism|2009|497